miércoles, 17 de mayo de 2017

Journal for ImmunoTherapy of Cancer | Commentary/Editorials

Journal for ImmunoTherapy of Cancer | Commentary/Editorials

Biomed Central

Journal for ImmunoTherapy of Cancer

JITC logo

Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC)


Section edited by Christian Capitini, MD
Reaction to and/or perspectives on significant events in the field in the basic science area. May address a critical challenge, elaborate or extend a conversation of a focal article, provide an application of a theoretical perspective, or shed light on a particular issue in the field.


    It’s a long way to the top (if you want to personalize immunotherapy)

    Harnessing the immune system to attack tumor cells by targeting tumor-associated or –preferably– tumor-specific antigens has emerged as a promising but challenging treatment option for malignant lymphomas. Fol...
    Sarah Haebe and Oliver Weigert
    Journal for ImmunoTherapy of Cancer 2017 5:6
    Published on: 17 January 2017

    NLRC5, a promising new entry in tumor immunology

    The recent use of T cell-based cancer immunotherapies, such as adoptive T-cell transfer and checkpoint blockade, yields increasing clinical benefit to patients with different cancer types. However, decrease of...
    Sonia T. Chelbi and Greta Guarda
    Journal for ImmunoTherapy of Cancer 2016 4:39
    Published on: 19 July 2016

    Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule

    The Common Rule is a set of ethical principles that provide guidance on the management of human subjects taking part in biomedical and behavioral research in the United States. The elements of the Common Rule ...
    Howard L. Kaufman, Lisa H. Butterfield, Pierre G. Coulie, Sandra Demaria, Robert L. Ferris, Jérôme Galon, Samir N. Khleif, Ira Mellman, Pamela S. Ohashi, Willem W. Overwijk, Suzanne L. Topalian and Francesco M. Marincola
    Journal for ImmunoTherapy of Cancer 2016 4:37
    Published on: 21 June 2016

    How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapy

    Mounting an immune response sufficient to eradicate a tumor is the goal of modern immunotherapy. Single agent therapies with checkpoint inhibitors or costimulatory molecule agonists are effective only for a sm...
    Stefanie N. Linch and William L. Redmond
    Journal for ImmunoTherapy of Cancer 2016 4:31
    Published on: 21 June 2016

    Natural killer cell immunotherapy to target stem-like tumor cells

    Advances in cancer immunotherapy are leading to its increasing and successful application for the treatment of solid–tissue cancers. Despite the recent advances there are still significant barriers, in particu...
    Steven K. Grossenbacher, Robert J. Canter and William J. Murphy
    Journal for ImmunoTherapy of Cancer 2016 4:19
    Published on: 19 April 2016

    Targetless T cells in cancer immunotherapy

    Attention has recently focused on new cancer immunotherapy protocols aiming to activate T cell mediated anti-tumor responses. To this end, administration of antibodies that target inhibitory molecules regulati...
    Per thor Straten and Federico Garrido
    Journal for ImmunoTherapy of Cancer 2016 4:23
    Published on: 19 April 2016

    A role for pre-mNK cells in tumor progression

    The innate and adaptive immune systems have evolved together to fight infection and cancerous tissues. The innate immune system emerges first with the adaptive immune system following, both ostensibly being br...
    Carolyn Rosinsky and Paul Andrew Antony
    Journal for ImmunoTherapy of Cancer 2016 4:16
    Published on: 15 March 2016

No hay comentarios:

Publicar un comentario